Trial · NCT02882854
Guanfacine for PONV and Pain After Sinus Surgery
NCT02882854, Not applicable, Completed, Vanderbilt University Medical Center; results first posted 2019-01-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Guanfacine for PONV and Pain After Sinus Surgery. Trials, record NCT02882854. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02882854
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Guanfacine for PONV and Pain After Sinus Surgery
- NCT number
- NCT02882854
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 84 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Postoperative Nausea and Vomiting, Pain, Postoperative
- Interventions
- Guanfacine, Placebo
- First posted
- 2016-08-30
- Last updated
- 2019-01-03
- Results first posted
- 2019-01-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | 15 minutes after arriving in PACU | Comparison of PONV Score of assessments done at 15 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea |
| Primary | Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | 30 minutes after arriving in PACU | Comparison of PONV Score of assessments done at 30 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea |
| Primary | Comparison of PONV Score of Assessments Done at 60 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | 60 minutes after arriving in PACU | Comparison of PONV Score of assessments done at 60 minutes after arrival in PACU using the nVRS when 0 is no nausea and 10 is worst nausea |
| Primary | Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS) | 24 hours post op | PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea. |
| Secondary | Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS) | 15, 30, 60 minutes after arriving in PACU | Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain |
| Secondary | Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS) | 24 hours postop | Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain |
| Secondary | Total Narcotic Requirement in PACU | Time frame between arrival and discharge in PACU, approximately 90 minutes | Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay |
| Secondary | Number of Doses of PONV Treatment Administered in PACU | Time frame between arrival and discharge in PACU, approximately 90 minutes | |
| Secondary | PACU Length of Stay in Minutes | Time frame between arrival and discharge in PACU, approximately 90 minutes |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | 15 minutes after arriving in PACU | 15 minute nVRS datapoint was not available for 2 participants in the Placebo group | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | 30 minutes after arriving in PACU | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Comparison of PONV Score of Assessments Done at 60 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | 60 minutes after arriving in PACU | nVRS data was not available for 1 participant in the Guanfacine group | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Postoperative Nausea Assessment Using 11-point Nausea Scale (nVRS) | 24 hours post op | Only 70 patients (32 in guanfacine arm; 38 in placebo arm) responded to follow-up phone call and provided PONV data at the 24 hour timepoint. | score on a scale | MEDIAN |
| SECONDARY | Maximum Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS) | 15, 30, 60 minutes after arriving in PACU | Data unavailable for 2 participants in the placebo group at 15 minute time point, 1 participant in the placebo group at the 30 minute time point, | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Postoperative Pain Assessment Using 11-point Visual/Verbal Analog (VAS) | 24 hours postop | Based on only 71 participants to post operative questionnaire. | score on a scale | MEDIAN |
| SECONDARY | Total Narcotic Requirement in PACU | Time frame between arrival and discharge in PACU, approximately 90 minutes | Data was not available for 1 participant in the placebo group. | morphine equivalents | MEDIAN |
| SECONDARY | Number of Doses of PONV Treatment Administered in PACU | Time frame between arrival and discharge in PACU, approximately 90 minutes | Data missing for1 participants in the placebo group and 1 participant in the Guanfacine group. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | PACU Length of Stay in Minutes | Time frame between arrival and discharge in PACU, approximately 90 minutes | minutes | MEDIAN |
Source ClinicalTrials.gov
Results by group50
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Guanfacine | None (nVRS 0) | 35 | Participants | |
| Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Placebo | None (nVRS 0) | 33 | Participants | |
| Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Guanfacine | Mild (nVRS 1-5) | 1 | Participants | |
| Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Placebo | Mild (nVRS 1-5) | 2 | Participants | |
| Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Guanfacine | Moderate/Severe (nVRS 6-10) | 3 | Participants | |
| Comparison of PONV Score of Assessments Done at 15 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Placebo | Moderate/Severe (nVRS 6-10) | 4 | Participants | |
| Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Guanfacine | None (nVRS 0) | 34 | Participants | |
| Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Placebo | None (nVRS 0) | 34 | Participants | |
| Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Guanfacine | Mild (nVRS 1-5) | 4 | Participants | |
| Comparison of PONV Score of Assessments Done at 30 Minutes After Arrival in PACU Using 11-point Nausea Scale (nVRS) | Placebo | Mild (nVRS 1-5) | 5 | Participants |
1 to 10 of 50Source ClinicalTrials.gov
See all 50 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Guanfacine | 40 | |
| Overall Study | STARTED | Placebo | 44 | |
| Overall Study | COMPLETED | Guanfacine | 39 | |
| Overall Study | COMPLETED | Placebo | 41 | |
| Overall Study | NOT COMPLETED | Guanfacine | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Guanfacine | 0 | 40 |
| Total, all-cause mortality | Placebo | 0 | 44 |
| Total, other adverse events | Guanfacine | 0 | 40 |
| Total, other adverse events | Placebo | 0 | 44 |
| Total, serious adverse events | Guanfacine | 0 | 40 |
| Total, serious adverse events | Placebo | 0 | 44 |
Source ClinicalTrials.gov
Papers28
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Guanfacine vs Placebo: deaths from any cause | Trial comparisons |
| Guanfacine vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02882854
GET https://conductscience.org/api/trials/v1/NCT02882854/results?page=2